,i #aahth ,,congress #ast ,session ,h4 ,r4 #deca ,,in ,,the ,,house ,,of ,,representatives ,july #aa1 #bjbc,mr4 ,guthrie 7for himself and ,ms4 ,kuster7 introduced the following bill2 which was referred to the ,committee on ,energy and ,commerce1 and in addition to the ,committees on the ,judiciary1 and ,education and the ,workforce1 for a period to be subsequently determined by the ,speaker1 in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned ,a ,,bill ,to reauthorize certain programs that provide for opioid use disorder prevention1 recovery1 and treatment1 and for other purposes4 #a4 ,short title ,this ,act may be cited as the ,support for ,patients and ,communities ,reauthorization ,act4 #b4 ,table of contents ,the table of contents for this ,act is as follows3 ,sec4 #a4 ,short title4,sec4 #b4 ,table of contents4,title ,i--,public ,health,sec4 #aja4 ,monitoring and education regarding infections associated with illicit drug use and other risk factors4,sec4 #ajb4 ,preventing overdoses of controlled substances4,sec4 #ajc4 ,residential treatment programs for pregnant and postpartum women4,sec4 #ajd4 ,first responder training4,sec4 #aje4 ,building communities of recovery4,sec4 #ajf4 ,national ,peer-,run ,training and ,technical ,assistance ,center for ,addiction ,recovery ,support4,sec4 #ajg4 ,comprehensive opioid recovery centers4,sec4 #ajh4 ,grants to address the problems of persons who experience violence related stress4,sec4 #aji4 ,mental and behavioral health education and training grants4,sec4 #aaj4 ,loan repayment program for the substance use disorder treatment workforce4,sec4 #aaa4 ,pilot program for public health laboratories to detect fentanyl and other synthetic opioids4,sec4 #aab4 ,monitoring and reporting of child1 youth1 and adult trauma4,sec4 #aac4 ,task force to develop best practices for trauma-informed identification1 referral1 and support4,sec4 #aad4 ,treatment1 recovery1 and workforce support grants4,sec4 #aae4 ,grant program for ,state and ,tribal response to opioid use disorders4,sec4 #aaf4 ,references to opioid overdose reversal agents in ,,hhs grant programs4,sec4 #aag4 ,addressing other concurrent substance use disorders through grant program for ,state and ,tribal response to opioid use disorders4,sec4 #aah4 ,providing for a study on the effects of remote monitoring on individuals who are prescribed opioids4,title ,,ii--,controlled ,substances,sec4 #bja4 ,delivery of certain substances by a pharmacy to an administering practitioner4,sec4 #bjb4 ,reviewing the scheduling of approved products containing a combination of buprenorphine and naloxone4,sec4 #bjc4 ,combating illicit xylazine4,sec4 #bjd4 ,technical corrections4,title ,,iii--,medicaid,sec4 #cja4 ,extending requirement for ,state ,medicaid plans to provide coverage for medication-assisted treatment4,sec4 #cjb4 ,expanding required reports on ,t-,,msis substance use disorder data to include mental health condition data4,sec4 #cjc4 ,monitoring prescribing of antipsychotic medications4 ,i ,public ,health #aja4 ,monitoring and education regarding infections associated with illicit drug use and other risk factors ,section #cag,n of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bdg;b-#ae7 is amended-- 7#a7 in the section heading1 by striking ,surveillance and and inserting ,monitoring and2 and 7#b7 in subsection 7d71 by striking fiscal years #bjai through #bjbc and inserting fiscal years #bjbd through #bjbh4 #ajb4 ,preventing overdoses of controlled substances 7a7 ,evidence-,based prevention grants ,section #cib;,a7a77#b77;,d7 of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bhj;b-#a7;a77#b77;,d77 is amended by inserting after new and emerging public health crises the following3 1 such as the fentanyl crisis14 7b7 ,authorization of appropriations ,section #cib;,a7e7 of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bhj;b-#a7;e77 is amended by striking #dif1jjj1jjj for each of fiscal years #bjai through #bjbc and inserting #eje1egi1jjj for each of fiscal years #bjbd through #bjbh4 #ajc4 ,residential treatment programs for pregnant and postpartum women ,section #ejh7s7 of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bij;bb-#a7s77 is amended by striking #bi1ica1jjj for each of fiscal years #bjai through #bjbc and inserting #ch1ica1jjj for each of fiscal years #bjbd through #bjbh4 #ajd4 ,first responder training ,section #edf7;h7 of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bij;ee-#a7;h77 is amending by striking #cf1jjj1jjj for each of fiscal years #bjai through #bjbc and inserting #ef1jjj1jjj for each of fiscal years #bjbd through #bjbh4 #aje4 ,building communities of recovery ,section #edg7;f7 of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bij;ee-#b7;f77 is amended by striking #e1jjj1jjj for each of fiscal years #bjai through #bjbc and inserting #af1jjj1jjj for each of fiscal years #bjbd through #bjbh4 #ajf4 ,national ,peer-,run ,training and ,technical ,assistance ,center for ,addiction ,recovery ,support ,section #edg;,a7e7 of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bij;ee-#b;a7e77 is amended by striking #a1jjj1jjj for each of fiscal years #bjai through #bjbc and inserting #b1jjj1jjj for each of fiscal years #bjbd through #bjbh4 #ajg4 ,comprehensive opioid recovery centers 7a7 ,reauthorization ,section #eeb7;j7 of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bij;ee-#g7;j77 is amended by striking #bjai through #bjbc and inserting #bjbd through #bjbh4 7b7 ,documentation for evidence of capacity ,to carry out required activities ,section #eeb7;d7 of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bij;ee-#g7;d77 is amended by adding at the end the following3 7#c7 ,documentation 7,a7 ,in general ,evidence required to be provided under paragraph 7#a7 may be provided through a letter of intent from partner agencies or other relevant documentation 7as defined by the ,secretary74 7,b7 ,partner agency defined ,in this paragraph1 the term partner agency means a non-governmental organization or other public or private entity-- 7i7 the primary purpose of which is the delivery of mental health or substance use disorder treatment services2 and 7ii7 with which the applicant coordinates to provide the full continuum of treatment services 7as specified in subsection 7g77#a77;,b77 that the applicant is unable to offer on site4 4 7c7 ,center activities carried out through third parties ,section #eeb7;g7 of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bij;ee-#g7;g77 is amended in the matter preceding paragraph 7#a7 by striking ,each ,center shall and all that follows through subsection 7f73 and inserting the following3 ,each ,center shall1 at a minimum1 carry out the activities specified in this subsection directly1 through referral1 or through contractual arrangements4 ,if a ,center elects to carry out such activities through contractual arrangements1 the ,secretary may issue guidance on best practices to ensure that the ,center is capable of carrying out such activities1 including carrying out such activities through technology-enabled collaborative learning and capacity building models described in subsection 7f7 and coordinating the full continuum of treatment services specified in subparagraph 7,b74 ,such activities include the following34 #ajh4 ,grants to address the problems of persons who experience violence related stress ,section #ehb7;j7 of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bij;hh-#a7;j77 is amended by striking #fc1hhg1jjj for each of fiscal years #bjai through #bjbc and inserting #ic1hhg1jjj for each of fiscal years #bjbd through #bjbh4 #aji4 ,mental and behavioral health education and training grants ,section #gef7;f7 of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bid;e-#a7;f77 is amended by striking fiscal years #bjbc through #bjbg and inserting fiscal years #bjbd through #bjbh4 #aaj4 ,loan repayment program for the substance use disorder treatment workforce ,section #gha7;j7 of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bie;h7j77 is amended by striking #be1jjj1jjj for each of fiscal years #bjai through #bjbc and inserting #dj1jjj1jjj for each of fiscal years #bjbd through #bjbh4 #aaa4 ,pilot program for public health laboratories to detect fentanyl and other synthetic opioids ,section #gjaa7;d7 of the ,,support for ,patients and ,communities ,act 7#db ,u4,s4,c4 #bdg;d-#aj7;d77 is amended by striking fiscal years #bjai through #bjbc and inserting fiscal years #bjbd through #bjbh4 #aab4 ,monitoring and reporting of child1 youth1 and adult trauma ,section #gaca7;e7 of the ,,support for ,patients and ,communities ,act 7#db ,u4,s4,c4 #bdbt7e77 is amended by striking #b1jjj1jjj for each of fiscal years #bjai through #bjbc and inserting #i1jjj1jjj for each of fiscal years #bjbd through #bjbh4 #aac4 ,task force to develop best practices for trauma-informed identification1 referral1 and support ,section #gacb of the ,,support for ,patients and ,communities ,act 7,public ,law #aae-bga7 is amended-- 7#a7 in subsection 7g7-- 7,a7 in paragraph 7#a71 by striking and at the end2 7,b7 in paragraph 7#b71 by striking the period at the end and inserting 2 and2 and 7,c7 by adding at the end the following3 7#c7 additional reports and updates to existing reports1 as necessary4 2 and 7#b7 by striking subsection 7i74 #aad4 ,treatment1 recovery1 and workforce support grants ,section #gahc of the ,,support for ,patients and ,communities ,act 7#db ,u4,s4,c4 #bij;ee-#h7 is amended-- 7#a7 in subsection 7b71 by inserting each before for a period2 7#b7 by amending subsection 7c77#b7 to read as follows3 7#b7 ,rates ,the rates described in this paragraph are the following3 7,a7 ,the amount by which the average rate of drug overdose deaths in the ,state1 adjusted for age1 for the period of #e calendar years for which there is available data1 including if necessary provisional data1 immediately preceding the grant cycle 7which shall be the period of calendar years #bjah through #bjbb for the first grant cycle following the enactment of the ,support for ,patients and ,communities ,reauthorization ,act7 is above the average national overdose mortality rate1 as determined by the ,director of the ,centers for ,disease ,control and ,prevention1 for the same period4 7,b7 ,the amount by which the average rate of unemployment for the ,state1 based on data provided by the ,bureau of ,labor ,statistics1 for the period of #e calendar years for which there is available data1 including if necessary provisional data1 immediately preceding the grant cycle 7which shall be the period of calendar years #bjah through #bjbb for the first grant cycle following the enactment of the ,support for ,patients and ,communities ,reauthorization ,act7 is above the national average for the same period4 7,c7 ,the amount by which the average rate of labor force participation in the ,state1 based on data provided by the ,bureau of ,labor ,statistics1 for the period of #e calendar years for which there is available data1 including if necessary provisional data1 immediately preceding the grant cycle 7which shall be the period of calendar years #bjah through #bjbb for the first grant cycle following the enactment of the ,support for ,patients and ,communities ,reauthorization ,act7 is below the national average for the same period4 2 7#c7 in subsection 7g7-- 7,a7 in paragraphs 7#a7 and 7#c71 by redesignating subparagraphs 7,a7 and 7,b7 as clauses 7i7 and 7ii71 respectively1 and adjusting the margins accordingly2 7,b7 by redesignating paragraphs 7#a7 through 7#c7 as subparagraphs 7,a7 through 7,c71 respectively1 and adjusting the margins accordingly2 7,c7 by striking ,an entity and inserting the following3 7#a7 ,in general ,an entity 2 and 7,d7 by adding at the end the following3 7#b7 ,transportation services ,an entity receiving a grant under this section may use the funds for providing transportation for individuals to participate in an activity supported by a grant under this section1 which transportation shall be to or from a place of work or a place where the individual is receiving vocational education or job training services or receiving services directly linked to treatment of or recovery from a substance use disorder4 2 7#d7 in subsection 7j7-- 7,a7 in paragraph 7#a71 by inserting for each grant cycle after grant period2 and 7,b7 in paragraph 7#b7-- 7i7 in the matter preceding subparagraph 7,a7-- 7,i7 by striking the preliminary report and inserting each preliminary report2 and 7,,ii7 by inserting for the grant cycle after final report2 and 7ii7 in subparagraph 7,a71 by striking 7g77#c7 and inserting 7g77#a77;,c72 and 7#e7 in subsection 7k71 by striking #e1jjj1jjj for each of fiscal years #bjai through #bjbc and inserting #ab1jjj1jjj for each of fiscal years #bjbd through #bjbh4 #aae4 ,grant program for ,state and ,tribal response to opioid use disorders ,section #ajjc7;b77#d77;,a7 of the #bast ,century ,cures ,act 7#db ,u4,s4,c4 #bij;ee-#c;a7b77#d77;,a77 is amended after which may include drugs or devices approved1 cleared1 or otherwise legally marketed under the ,federal ,food1 ,drug1 and ,cosmetic ,act by inserting or fentanyl or xylazine test strips4 #aaf4 ,references to opioid overdose reversal agents in ,,hhs grant programs 7a7 ,in general ,the ,secretary of ,health and ,human ,services shall ensure that1 whenever the ,department of ,health and ,human ,services issues a regulation1 guidance1 or other document for any grant program addressing opioid misuse and use disorders1 any reference to an opioid overdose reversal agent 7such as a reference to naloxone7 is inclusive of any opioid overdose reversal agent that has been approved or otherwise authorized for use by the ,food and ,drug ,administration4 7b7 ,existing references 7#a7 ,update ,not later than the end of calendar year #bjbc1 the ,secretary of ,health and ,human ,services shall update all references described in paragraph 7#b7 to be inclusive of any opioid overdose reversal agent that has been approved or otherwise authorized for use by the ,food and ,drug ,administration4 7#b7 ,references ,a reference described in this paragraph is any reference to an opioid overdose reversal agent 7such as naloxone7 in any regulation1 guidance1 or other document of the ,department of ,health and ,human ,services that-- 7,a7 was issued before the date of enactment of this ,act2 and 7,b7 is for-- 7i7 the grant program for ,state and ,tribal response to opioid use disorders under section #ajjc of the #bast ,century ,cures ,act 7#db ,u4,s4,c4 #bij;ee-#c note2 commonly referred to as ,state ,opioid ,response ,grants and ,tribal ,opioid ,response ,grants72 or 7ii7 the grant program for priority substance use disorder prevention needs of regional and national significance under section #eaf of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bij;bb-#bb74 #aag4 ,addressing other concurrent substance use disorders through grant program for ,state and ,tribal response to opioid use disorders 7a7 ,additional use of funds ,section #ajjc7;b7 of the #bast ,century ,cures ,act 7#db ,u4,s4,c4 #bij;ee-#c note7 is amended by adding at the end the following3 7#e7 ,other concurrent substance use disorders ,the ,secretary may authorize the recipient of a grant under this subsection1 in addition to using the grant for activities described in paragraph 7#d7 with respect to opioid misuse and use disorders and stimulant misuse and use disorders1 to use the grant to for similar activities with respect to other concurrent substance use disorders4 4 7b7 ,annual report to ,congress ,section #ajjc7;f7 of the #bast ,century ,cures ,act 7#db ,u4,s4,c4 #bij;ee-#c note7 is amended-- 7#a7 in paragraph 7#b71 strike and at the end2 7#b7 in paragraph 7#c71 strike the period at the end and insert a semicolon2 and 7#c7 by adding at the end the following3 7#d7 the amount of funds each ,state that receiving a grant under subsection 7b7 received for the #ab-month grant cycle covered by the report2 7#e7 the amount of grant funds each such ,state spent for such grant cycle1 disaggregated by the uses for which such funds were spent1 including each allowable use under paragraphs 7#d7 and 7#e7 of subsection 7b72 7#f7 how many such ,states for such grant cycle did not spend the all of the grant funds before such grant cycle expired2 7#g7 how many such ,states for such grant cycle requested waivers to extend the grant cycle2 and 7#h7 challenges for such ,states to spend all of the funds allocated and the reason for such challenges1 including to what extent reporting requirements or other requirements placed an increased burden on the ability of such ,states to spend all of the funds4 4 7c7 ,other concurrent substance use disorders defined ,section #ajjc7;h7 of the #bast ,century ,cures ,act 7#db ,u4,s4,c4 #bij;ee-#c note7 is amended-- 7#a7 by redesignating paragraphs 7#b7 through 7#d7 as paragraphs 7#c7 through 7#e72 and 7#b7 by inserting before paragraph 7#c71 as redesignated1 the following3 7#b7 ,other concurrent substance use disorders ,the term other substance use disorders includes alcohol use disorders co-occurring with opioid misuse and use disorders and alcohol use disorders co-occurring with stimulant misuse and use disorders1 including polydrug use and alcohol use disorder4 4 7d7 ,rule of construction ,nothing in this ,act or the amendments made by this ,act shall be construed to change the allocation of funds among grantees pursuant to the minimum allocations and formula methodology under section #ajjc of the #bast ,century ,cures ,act 7#db ,u4,s4,c4 #bij;ee-#c note74 #aah4 ,providing for a study on the effects of remote monitoring on individuals who are prescribed opioids 7a7 ,in general ,not later than #ah months after the date of enactment of this ,act1 the ,comptroller ,general of the ,united ,states shall conduct a study and submit to the ,committee on ,energy and ,commerce of the ,house of ,representatives and the ,committee on ,health1 ,education1 ,labor1 and ,pensions and the ,committee on ,finance of the ,senate a report on the use of remote monitoring with respect to individuals who are prescribed opioids4 7b7 ,report ,the report described in subsection 7a7 shall include-- 7#a7 an assessment of scientific evidence related to the efficacy1 individual outcomes1 and potential cost savings associated with remote monitoring for individuals who are prescribed opioids compared to such individuals who are not so monitored2 7#b7 an assessment of the current prevalence of remote monitoring for individuals who are prescribed opioids1 including the use of such monitoring for such individuals in other countries2 and 7#c7 recommendations to improve availability1 access1 and coverage for remote monitoring for individuals who are prescribed opioids1 including through changes to ,federal health care programs 7as defined in section #aabh;,b of the ,social ,security ,act 7#db ,u4,s4,c4 #acbj;a-#g;b77 and1 if determined appropriate by the ,comptroller ,general1 an identification of cohorts of individuals who stand to benefit the most from remote monitoring when prescribed opioids4 ,,ii ,controlled ,substances #bja4 ,delivery of certain substances by a pharmacy to an administering practitioner ,paragraph 7#b7 of section #cji;,a7a7 of the ,controlled ,substances ,act 7#ba ,u4,s4,c4 #hbi;a7a77 is amended to read as follows3 7#b7 the controlled substance is a drug in schedule ,,iii1 ,,iv1 or ,v that is1 pursuant to the approval or licensure of such drug under the ,federal ,food1 ,drug1 and ,cosmetic ,act or section #cea of the ,public ,health ,service ,act1 to be administered by1 or under the supervision of1 the practitioner2 4 #bjb4 ,reviewing the scheduling of approved products containing a combination of buprenorphine and naloxone 7a7 ,secretary of ,,hhs ,the ,secretary of ,health and ,human ,services shall1 consistent with the requirements and procedures set forth in sections #bja and #bjb of the ,controlled ,substances ,act 7#ba ,u4,s4,c4 #haa2 #hab7-- 7#a7 review the relevant data pertaining to the scheduling of products containing a combination of buprenorphine and naloxone that have been approved under section #eje of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cee72 and 7#b7 if appropriate1 request that the ,attorney ,general initiate rulemaking proceedings to revise the schedules accordingly with respect to such products4 7b7 ,attorney ,general ,the ,attorney ,general shall review any request made by the ,secretary of ,health and ,human ,services under subsection 7a77#b7 and determine whether to initiate proceedings to revise the schedules in accordance with the criteria set forth in sections #bja and #bjb of the ,controlled ,substances ,act 7#ba ,u4,s4,c4 #haa2 #hab74 #bjc4 ,combating illicit xylazine 7a7 ,definitions 7#a7 ,in general ,in this section1 the term xylazine has the meaning given the term in paragraph 7#fj7 of section #ajb of the ,controlled ,substances ,act1 as added by paragraph 7#b74 7#b7 ,controlled ,substances ,act ,section #ajb of the ,controlled ,substances ,act 7#ba ,u4,s4,c4 #hjb7 is amended-- 7,a7 by redesignating the second paragraph 7#eg7 7relating to serious drug felony7 and paragraph 7#eh7 as paragraphs 7#eh7 and 7#ei71 respectively2 7,b7 by moving the margin of paragraph 7#eg7 #b ems to the left2 7,c7 by moving the margins of paragraphs 7#eh7 and 7#ei71 as redesignated1 #b ems to the left2 and 7,d7 by adding at the end the following3 7#fj7 7,a7 ,the term xylazine means the substance xylazine as well as its salts1 isomers1 and salts of isomers whenever the existence of such salts1 isomers1 and salts of isomers is possible4 7,b7 ,except as provided in subparagraph 7,e71 such term does not include a substance described in subparagraph 7,a7 to the extent-- 7i7 such substance is used or intended for use in animals other than humans and is an animal drug that has been approved by the ,secretary of ,health and ,human ,services under section #eab of the ,federal ,food1 ,drug1 and ,cosmetic ,act1 conditionally approved under section #ega of such ,act1 index listed under section #egc of such ,act1 or subject to an exemption for investigational use under section #eab7;j7 of such ,act1 and such use or intended use conforms to the approved application or index listing1 including the manufacturing1 importation1 holding1 or distribution for such use2 7ii7 such substance is used or intended for use in animals other than humans as permitted under section #eab7;a77#d7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act2 7iii7 such substance is manufactured1 imported1 held1 distributed1 or used-- 7,i7 as an active pharmaceutical ingredient for manufacturing an animal drug approved under section #eab of the ,federal ,food1 ,drug1 and ,cosmetic ,act1 conditionally approved under section #ega of such ,act1 index listed under section #egc of the such ,act1 or subject to an exemption for investigational use under section #eab7;j7 of such ,act2 or 7,,ii7 as a bulk chemical for pharmaceutical compounding of a new animal drug 7as defined in section #bja of the ,federal ,food1 ,drug1 and ,cosmetic ,act7 by or under the direct supervision of a licensed pharmacist or by or on the lawful written or oral order of a licensed veterinarian within the context of a veterinarian-client-patient relationship1 as defined by the ,secretary of ,health and ,human ,services2 7iv7 such substance is held or used as a compounded new animal drug described in clause 7iii77,,ii72 7v7 such substance is otherwise used or intended for use in animals other than humans1 and such use is approved or otherwise authorized under the ,federal ,food1 ,drug1 and ,cosmetic ,act provided any such use conforms to such approval or authorization2 7vi7 such substance is subject to an exemption for investigational use under section #eje7;i7 or #ebj7;g7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act2 7vii7 such substance is imported1 held1 distributed1 or used for the development1 manufacturing1 or performance of tests for detection of xylazine 7including xylazine used as a control or calibration standard7 by persons who are professionally1 regularly1 and lawfully engaged in such activities2 or 7viii7 such substance is held1 distributed1 or used in a commercially manufactured test for the detection of xylazine1 provided such test does not contain xylazine in a form that can be extracted4 7,c7 ,notwithstanding subparagraph 7,b71 the ,attorney ,general may place any substance listed in such subparagraph on a schedule under section #bjb in accordance with subsections 7a7 through 7c7 of section #bja4 7,d7 ,nothing in this paragraph shall be construed as a basis for inferring that a compounded animal drug is not a new animal drug subject to the requirements of section #eab7;a7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act4 7,e7 ,if any person prescribes1 dispenses1 distributes1 manufactures1 or imports xylazine for human use1 such person shall be considered to have prescribed1 dispensed1 distributed1 manufactured1 or imported xylazine not subject to an exclusion under subparagraph 7,b74 4 7b7 ,placement of xylazine on schedule ,,iii ,schedule ,,iii in section #bjb7;c7 of the ,controlled ,substances ,act 7#ba ,u4,s4,c4 #hab7;c77 is amended by adding at the end the following3 7f7 ,xylazine4 4 7c7 ,report to ,congress on xylazine 7#a7 ,initial report ,not later than #a year after the date of enactment of this ,act1 the ,attorney ,general1 acting through the ,administrator of the ,drug ,enforcement ,administration and in coordination with the ,commissioner of ,food and ,drugs1 shall submit to ,congress a report on the prevalence of illicit use of xylazine in the ,united ,states and the impacts of such use1 including-- 7,a7 where the drug is being diverted2 7,b7 where the drug is originating2 7,c7 whether any analogues to such drug present a substantial risk of abuse2 7,d7 whether and to what extent the illicit supply of xylazine derives from the licit supply chain2 and 7,e7 recommendations for ,congress with respect to whether xylazine should be transferred to another schedule under section #bjb of the ,controlled ,substances ,act 7#ba ,u4,s4,c4 #hab74 7#b7 ,additional report ,not later than #d years after the date of enactment of this ,act1 the ,attorney ,general1 acting through the ,administrator of the ,drug ,enforcement ,administration and in coordination with the ,commissioner of ,food and ,drugs1 shall submit to ,congress a report updating ,congress on the prevalence of xylazine trafficking1 misuse1 and proliferation in the ,united ,states1 including recommendations for ,congress with respect to whether xylazine should be transferred to another schedule under section #bjb of the ,controlled ,substances ,act 7#ba ,u4,s4,c4 #hab7 or removed from schedule ,,iii of such part4 #bjd4 ,technical corrections ,effective as if included in the enactment of ,public ,law #aag-cbh-- 7#a7 section #abeb7;a7 of division ,,ff of ,public ,law #aag-cbh is amended1 in the matter being inserted into section #cjb7;e7 of the ,controlled ,substances ,act1 by striking #cjc7;g7 and inserting #cjc7;h72 7#b7 section #abfb of division ,,ff of ,public ,law #aag-cbh is amended-- 7,a7 in subsection 7a7-- 7i7 in the matter preceding paragraph 7#a71 by striking #cjc7;g7 and inserting #cjc7;h72 7ii7 in the matter being stricken by subsection 7a77#b71 by striking 7g77#a7 and inserting 7h77#a72 and 7iii7 in the matter being inserted by subsection 7a77#b71 by striking 7g7 ,practitioners and inserting 7h7 ,practitioners2 and 7,b7 in subsection 7b7-- 7i7 in the matter being stricken by paragraph 7#a71 by striking #cjc7;g77#a7 and inserting #cjc7;h77#a72 7ii7 in the matter being inserted by paragraph 7#a71 by striking #cjc7;g7 and inserting #cjc7;h72 7iii7 in the matter being stricken by paragraph 7#b77;,a71 by striking #cjc7;g77#b7 and inserting #cjc7;h77#b72 7iv7 in the matter being stricken by paragraph 7#c71 by striking #cjc7;g77#b77;,b7 and inserting #cjc7;h77#b77;,b72 7v7 in the matter being stricken by paragraph 7#e71 by striking #cjc7;g7 and inserting #cjc7;h72 and 7vi7 in the matter being stricken by paragraph 7#f71 by striking #cjc7;g7 and inserting #cjc7;h72 and 7#c7 section #abfc7;b7 of division ,,ff of ,public ,law #aag-cbh is amended-- 7,a7 by striking #cjc7;g77#b7 and inserting #cjc7;h77#b72 and 7,b7 by striking 7#ba ,u4,s4,c4 #hbc7;g77#b77 and inserting 7#ba ,u4,s4,c4 #hbc7;h77#b774 ,,iii ,medicaid #cja4 ,extending requirement for ,state ,medicaid plans to provide coverage for medication-assisted treatment 7a7 ,in general ,section #aije of the ,social ,security ,act 7#db ,u4,s4,c4 #acif;d7 is amended-- 7#a7 in subsection 7a77#bi71 by striking for the period beginning ,october #a1 #bjbj1 and ending ,september #cj1 #bjbe1 and inserting beginning on ,october #a1 #bjbj12 and 7#b7 in subsection 7ee77#b71 by striking for the period specified in such paragraph1 if before the beginning of such period the ,state certifies to the satisfaction of the ,secretary and inserting if such ,state certifies1 not less than every #e years and to the satisfaction of the ,secretary14 7b7 ,conforming amendment ,section #ajjf7;b77#d77;,a7 of the ,substance ,use-,disorder ,prevention that ,promotes ,opioid ,recovery and ,treatment for ,patients and ,communities ,act 7#db ,u4,s4,c4 #acif;a note7 is amended by striking 1 and before ,october #a1 #bjbe4 #cjb4 ,expanding required reports on ,t-,,msis substance use disorder data to include mental health condition data 7a7 ,in general ,section #ajae7;a7 of the ,,support for ,patients and ,communities ,act 7#db ,u4,s4,c4 #acbj;d-#b note7 is amended-- 7#a7 in the heading1 by striking substance use disorder data book and inserting behavioral health data book2 7#b7 in paragraph 7#b7-- 7,a7 in the matter preceding subparagraph 7,a71 by inserting 1 including as updated in accordance with paragraph 7#c71 after paragraph 7#a72 7,b7 in subparagraph 7,a71 by inserting 1 mental health condition1 or a mental health condition co-occurring with substance use disorder after substance use disorder2 7,c7 in subparagraph 7,b71 by inserting and mental health treatment services after substance use disorder treatment services2 7,d7 in subparagraph 7,c7-- 7i7 by inserting 1 mental health condition1 or a mental health condition co-occurring with a substance use disorder diagnosis after substance use disorder diagnosis2 and 7ii7 by inserting or mental health treatment services1 respectively1 after substance use disorder treatment services2 7,e7 in subparagraph 7,d71 by inserting 1 mental health condition1 or a mental health condition co-occurring with substance use disorder after substance use disorder diagnosis2 7,f7 in subparagraph 7,e71 by inserting or mental health treatment after substance use disorder treatment2 and 7,g7 in subparagraph 7,f71 by inserting 1 individuals with a mental health condition who receive mental health treatment services1 and individuals with a co-occurring mental health condition and substance use disorder who receive substance use disorder treatment services and mental health treatment services1 after substance use disorder treatment services2 and 7#c7 in paragraph 7#c71 by striking through #bjbd4 7b7 ,application ,the amendments made by subsection 7a77#a7 shall apply beginning with respect to the first update made pursuant to section #ajae7;a77#c7 of the ,,support for ,patients and ,communities ,act 7#db ,u4,s4,c4 #acbj;d-#b note7 after the date that is #ab months after the date of enactment of this ,act4 #cjc4 ,monitoring prescribing of antipsychotic medications ,section #aijb7oo7 of the ,social ,security ,act 7#db ,u4,s4,c4 #acif;a7oo77 is amended-- 7#a7 in paragraph 7#a77;,b7-- 7,a7 in the subparagraph heading1 by striking by children2 and 7,b7 by inserting 1 and beginning on the date that is #bd months after the date of enactment of the ,support for ,patients and ,communities ,reauthorization ,act1 individuals over the age of #ah1 individuals receiving home and community-based services 7as defined in section #ihag7;a77#b77;,b7 of ,public ,law #aag-b71 and individuals residing in institutional care settings 7including nursing facilities and intermediate care facilities for individuals with intellectual disabilities7 enrolled1 after children enrolled2 and 7#b7 in paragraph 7#c7-- 7,a7 in subparagraph 7,a77ii71 by striking is a resident and inserting subject to subparagraph 7,c71 is a resident2 and 7,b7 by adding at the end the following new subparagraph3 7,c7 ,application in case of program to monitor antipsychotic medications ,subparagraph 7,a77ii7 shall not apply to the drug review and utilization requirement described in paragraph 7#a77;,b7 with respect to an individual to whom such subparagraph applies by reason of the amendments made by section #cjc7a7 of the ,support for ,patients and ,communities ,reauthorization ,act4 4